NCT02776059 is a Phase 2 clinical trial of Standard of care + pegfiltrastim in Alcoholic Hepatitis, sponsored by Timothy Morgan, MD.

Who is sponsoring NCT02776059?

NCT02776059 is sponsored by Timothy Morgan, MD.

What drugs are being tested in NCT02776059?

Interventions in NCT02776059: Standard of care + pegfiltrastim, Standard of care.

What condition does NCT02776059 study?

NCT02776059 studies Alcoholic Hepatitis.

Is NCT02776059 still recruiting?

NCT02776059 is currently completed. Last updated 29 September 2021.

Last reviewed 2021-09-29 · How we verify

NCT02776059

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pegfilgrastim in Patients With Alcoholic Hepatitis

Completed Phase 2 Last updated 29 September 2021

What this trial tests

Phase 2 trial testing Standard of care + pegfiltrastim in Alcoholic Hepatitis in 34 participants. Completed in 31 March 2021.

Timeline

21 January 2017

Primary endpoint
31 March 2020

31 March 2021

Quick facts

Lead sponsor	Timothy Morgan, MD
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	21 January 2017
Primary completion	31 March 2020
Estimated completion	31 March 2021
Sites	5 locations across United States

Drugs / interventions tested

Standard of care + pegfiltrastim — full drug profile →
Standard of care

Conditions studied

Alcoholic Hepatitis — all drugs for Alcoholic Hepatitis →

Sponsor

Timothy Morgan, MD — full company profile →

Who can join

18 and older, any sex, with Alcoholic Hepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, prospective, randomized trial of standard of care vs. standard of care + pegfilgrastim (Neulasta®) among patients with a clinical diagnosis of alcoholic hepatitis and DF≥32.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The knowns and unknowns of treatment for alcoholic hepatitis.
Sehrawat TS, Liu M, Shah VH. · · 2020 · cited 76× · PMID 32277902 · DOI 10.1016/s2468-1253(19)30326-7
Epidemiological Realities of Alcoholic Liver Disease: Global Burden, Research Trends, and Therapeutic Promise.
Xiao J, Wang F, Wong NK, Lv Y, et al · · 2020 · cited 28× · PMID 32690129 · DOI 10.3727/105221620x15952664091823
Interleukin-22 in alcoholic hepatitis and beyond.
Xiang X, Hwang S, Feng D, Shah VH, et al · · 2020 · cited 25× · PMID 32892258 · DOI 10.1007/s12072-020-10082-6
A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis.
Tayek JA, Stolz AA, Nguyen DV, Fleischman MW, et al · · 2022 · cited 23× · PMID 36267499 · DOI 10.1016/j.eclinm.2022.101689
Current Management and Future Treatment of Alcoholic Hepatitis.
Mitchell MC, Kerr T, Herlong HF. · · 2020 · cited 12× · PMID 34035720
Alcoholic Hepatitis.
Gougol A, Clemente-Sanchez A, Argemi J, Bataller R. · · 2021 · cited 7× · PMID 34584675 · DOI 10.1002/cld.1092
Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease.
Colli A, Fraquelli M, Prati D, Casazza G. · · 2023 · cited 6× · PMID 37278488 · DOI 10.1002/14651858.cd013532.pub2
The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
Vergis N, Atkinson SR, Thursz MR. · · 2019 · cited 5× · PMID 30791978 · DOI 10.1016/j.jhep.2019.01.016

Verify or expand the search:

Other recruiting trials for Alcoholic Hepatitis

Currently open trials in the same condition.

NCT06919458 — Short Course Steroids in Alcohol Associated Hepatitis · Phase 3 · recruiting
NCT06307964 — Intra-Hepatic Microbiota in Alcoholic Hepatitis · recruiting
NCT05006430 — Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis · Phase 1, PHASE2 · recruiting
NCT05018481 — HA35 Moderate Alcoholic Hepatitis (AH) Study · EARLY_PHASE1 · recruiting
NCT02473341 — Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02776059 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Timothy Morgan, MD
Last refreshed: 29 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02776059.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing